Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear receptor binding protein 2 (NRBP2)
- Target
- NRBP2
- Molecular classification
- Other (pseudokinase, not a classical receptor/enzyme/TF but a unique protein family member, "NRBP family")
01
Overview
Nuclear receptor binding protein 2 (NRBP2) is a conserved, cytoplasmic pseudokinase predominantly expressed in neural and some tumor tissues, predicted to have protein serine/threonine kinase activity but lacking demonstrated classical kinase function. It negatively regulates cell proliferation, invasion, and EMT, and promotes apoptosis in several cancer cell types, acting as a tumor suppressor. NRBP2 acts via the AMPK/mTOR signaling axis and is under epigenetic regulation. Loss or downregulation of NRBP2 is linked to worse outcomes in breast cancer and medulloblastoma, suggesting it is a prognostic and potentially therapeutic target in oncology. Although it was named for possible nuclear receptor interactions, no current evidence shows it binding nuclear receptors; its function appears primarily cytoplasmic.
- Other names
- Transformation-related gene 16 proteinTRG16PP9320DKFZp434P086transformation-related protein 16TRG-16nuclear receptor-binding protein 2pp9320
02
Mechanism of action
Not directly targeted by drugs; overexpression or knockdown alters cell survival and metastasis via modulation of the AMPK/mTOR pathway
03
Biological functions
Negative regulation of macroautophagyregulation of apoptosis (notably neural progenitor cells)regulation of cell proliferationnegative regulation of cell invasion and migrationinhibition of epithelial-to-mesenchymal transition (EMT)potential regulation of neural and tumor cell differentiation
04
Disease associations
Cancer (notably tumor suppressor in medulloblastoma, hepatocellular carcinoma, and breast cancer)potential biomarker for prognosis in breast cancerpossible role in other cancers
05
Safety considerations
Not established; no therapeutics are currently known to directly target NRBP2, so on-target/off-target effect data is lacking
06
Interacting drugs
None established as of current evidence; however, AMPK inhibitors (Compound C) and mTOR inhibitors (rapamycin) used experimentally to probe its pathway involvement
07
Biomarkers
Low NRBP2 expression is associated with poor prognosis in breast cancer and is a potential marker for aggressiveness in medulloblastoma
Beyond the preview
Go deeper on Nuclear receptor binding protein 2 (NRBP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuclear receptor binding protein 2 (NRBP2).